Therapeutic area
Rare and genetic disease
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.govMethods & limitations
Approvals since 2023
26
Originals, plus breakthrough or accelerated new uses
Recruiting Phase 2
16
Industry-sponsored
Recruiting Phase 3
13
Industry-sponsored
Recruiting Phase 4 (post-approval)
5
Industry-sponsored
Recent approvals
- Emcitate (Tiratricol) · Rare Thyroid NovelPriority reviewOrphanSep 28, 2026
To treat peripheral thyrotoxicosis in patients with MCT8 deficiency
- Tryngolza (Autoinjector) (Olezarsen Sodium) · Ionis Pharms INC Breakthrough therapyPriority reviewOrphanJun 24, 2026
- Idvynso (Doravirine, Islatravir) · Msd NovelApr 20, 2026
To treat HIV-1 infection (as a complete regimen) in adults to replace the current antiretroviral regimen in those who are virologically-suppressed on a stable antiretroviral regimen with no history of virologic treatment failure and no known substitutions associated with resistance to doravirine
- Avlayah (Tividenofusp Alfa-Eknm) · Denali Therapeutics Inc. NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanMar 24, 2026
To treat certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II)
- Yuviwel (Navepegritide) · Ascendis NovelAccelerated approvalPriority reviewOrphanFeb 27, 2026
To increase linear growth in pediatric patients 2 years and older with achondroplasia with open epiphyses
- Loargys (Pegzilarginase-Nbln) · Immedica Pharma Ab NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanFeb 23, 2026
To treat hyperarginemia in adults and pediatric patients two years and older with Arginase 1 Deficiency, in conjunction with dietary protein restriction
- Redemplo (Plozasiran Sodium) · Arrowhead NovelBreakthrough therapyOrphanNov 18, 2025
To reduce triglycerides in adults with familial chylomicronemia syndrome
- Kygevvi (Doxecitine, Doxribtimine) · Ucb INC NovelBreakthrough therapyPriority reviewOrphanNov 3, 2025
To treat thymidine kinase 2 deficiency in patients who start to show symptoms when they are 12 years old or younger
- Forzinity (Elamipretide Hydrochloride) · Stealth Biotheraps NovelAccelerated approvalPriority reviewOrphanSep 19, 2025
To improve muscle strength in patients with Barth syndrome weighing at least 30 kg
- Dawnzera (Autoinjector) (Donidalorsen Sodium) · Ionis Pharms INC NovelOrphanAug 21, 2025
To prevent attacks of hereditary angioedema
- Sephience (Sepiapterin) · Ptc Therap NovelOrphanJul 28, 2025
To treat hyperphenylalaninemia in patients with sepiapterin-responsive phenylketonuria, in conjunction with a phenylalanine-restricted diet
- Ekterly (Sebetralstat) · Kalvista NovelOrphanJul 3, 2025
To treat acute attacks of hereditary angioedema
- Andembry (Garadacimab-Gxii) · Csl Behring LLC NovelOrphanJun 16, 2025
To prevent attacks of hereditary angioedema
- Grafapex (Treosulfan) · Medexus NovelOrphanJan 21, 2025
For use in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome
- Tryngolza (Autoinjector) (Olezarsen Sodium) · Ionis Pharms INC NovelBreakthrough therapyPriority reviewOrphanDec 19, 2024
To treat familial chylomicronemia syndrome
Recruiting trials by phase
Industry-sponsored drug and biologic trials.
Most approvals since then, by company
- UCB1
Drugs in development
Investigational drugs in Phase 2 and 3 trials for conditions in this area, most trials first.
- IanalumabVAY736, VAY736 AIPhase 318 trials
Novartis · Primary Immune Thrombocytopenia (ITP), Systemic Lupus Erythematosus, Sjogren Syndrome
- AK117Phase 314 trials
Akeso · Advanced Malignant Tumors, ACUTE MYELOID LEUKEMIA; AML, Higher-risk Myelodysplastic Syndromes
- BrenipatideLY3537031Phase 313 trials
Eli Lilly · Alcohol Use Disorder, Irritable Bowel Syndrome, Depressive Disorder, Major
- PovorcitinibINCB054707, INCB54707Phase 312 trials
Incyte · Hidradenitis Suppurativa (HS), NonSegmental Vitiligo, Prurigo Nodularis
- APG-2575lisaftoclaxPhase 310 trials
Ascentage Pharma Group Inc. · CLL/SLL, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- AZD0120GC012FPhase 39 trials
AstraZeneca · Newly Diagnosed Multiple Myeloma (NDMM), Relapsed AL Amyloidosis, Refractory AL Amyloidosis
- EtentamigABBV-383, TNB-383BPhase 38 trials
AbbVie · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma, Amyloid Light Chain (AL) Amyloidosis
- CM336group, QiShen YiQi Dripping Pills 3 bagsPhase 37 trials
Keymed Biosciences Co.Ltd · Multiple Myeloma (MM), Primary Light-Chain Amyloidosis, Primary Immune Thrombocytopenia
- GlucocorticoidsPhase 37 trials
Novartis · VEXAS Syndrome, ANCA Associated Vasculitis (AAV), Anti-Glomerular Basement Membrane Disease
- IMVT-1402Phase 37 trials
Immunovant Sciences GmbH · Graves' Disease, Rheumatoid Arthritis, Subacute Cutaneous Lupus Erythematosus
- ObicetrapibPhase 37 trials
NewAmsterdam Pharma · Lipidemia, Preclinical Alzheimer's Disease, Antioxidant Absorption
- siRNAADX-038, ADX-324Phase 37 trials
ADARx Pharmaceuticals, Inc. · Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1
- AND017Phase 36 trials
Kind Pharmaceuticals LLC · Anemia Due to Chronic Kidney Disease, β -Thalassemia, Cancer-Related Anemia
- ElriterceptTAK-226, KER-050Phase 36 trials
Takeda · Myelodysplastic Syndromes, Myelofibrosis, Anemia
- LUM-201Phase 36 trials
Lumos Pharma · Growth Hormone Deficiency, Growth Hormone Deficiency (GHD), Obesity & Overweight
Largest recruiting Phase 3 trials
- A Long-Term Study of JNT-517 in Participants With PhenylketonuriaPivotal-lookingRecruiting
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT06628128 · 240 participants (planned) · Start Aug 11, 2025 · Primary completion Nov 1, 2027
Drug: JNT-517 · For: Phenylketonuria (PKU)
Sites: Gainesville, Florida; Tampa, Florida; Portland, Oregon · 12 sites in all
- A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 GangliosidosisPivotal-lookingRecruiting
Azafaros B.V.Industry
NCT07054515 · 147 participants (planned) · Start Jun 30, 2025 · Primary completion May 14, 2028
Drug: AZ-3102; Placebo · For: Niemann-Pick Type C Disease; GM1 Gangliosidosis; GM2 Gangliosidosis
Sites: Oakland, California; Minneapolis, Minnesota; Rochester, Minnesota · 39 sites in all
- A Study of JNT-517 in Participants With Phenylketonuria (PKU)Pivotal-lookingRecruiting
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT06971731 · 120 participants (planned) · Start Oct 20, 2025 · Primary completion Mar 1, 2028
Drug: JNT-517; JNT-517 Matching Placebo · For: Phenylketonuria
Sites: Los Angeles, California; Gainesville, Florida; Tampa, Florida · 26 sites in all
- A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)Pivotal-lookingRecruiting
Azafaros B.V.Industry
NCT07082725 · 72 participants (planned) · Start Jun 30, 2025 · Primary completion May 14, 2028
Drug: Nizubaglustat; Placebo · For: Niemann-Pick Type C Disease
Sites: Oakland, California; Minneapolis, Minnesota; Rochester, Minnesota · 34 sites in all
- A Study of Sepiapterin in Participants With Phenylketonuria (PKU)Pivotal-lookingRecruiting
PTC TherapeuticsIndustry
NCT06302348 · 56 participants (planned) · Start Mar 4, 2024 · Primary completion Feb 28, 2031
Drug: Sepiapterin · For: Phenylketonuria
Sites: Indianapolis, Indiana; Nedlands, Australia; North Adelaide, Australia · 14 sites in all
- A Pivotal Study of N-Acetyl-L-Leucine on Niemann-Pick Disease Type CPivotal-lookingRecruiting
IntraBio IncIndustry
NCT05163288 · 53 participants (planned) · Start Jun 30, 2022 · Primary completion Jun 12, 2030
Drug: N-Acetyl-L-Leucine · For: Niemann-Pick Disease, Type C
Sites: Rochester, Minnesota; Parkville, Australia; Prague, Czechia · 14 sites in all
- RAPA-501 Therapy for ALSPivotal-lookingRecruiting
Rapa Therapeutics LLCIndustry
NCT04220190 · 41 participants (planned) · Start Jan 2, 2025 · Primary completion Jul 1, 2027
Drug: RAPA-501 Autologous T stem cells · For: Amyotrophic Lateral Sclerosis
Sites: Boston, Massachusetts
- Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSHPivotal-lookingRecruiting
Ultragenyx Pharmaceutical IncIndustry
NCT02716246 · 36 participants (planned) · Start Apr 25, 2016 · Primary completion Mar 2029
Drug: UX111; Prophylactic Immunomodulatory (IM) Therapy and 2 more · For: MPS IIIA; Sanfilippo Syndrome; Sanfilippo A and 1 more
Sites: Columbus, Ohio; Pittsburgh, Pennsylvania; North Adelaide, Australia · 5 sites in all
- A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18Pivotal-lookingRecruiting
Amicus TherapeuticsIndustry
NCT04808505 · 36 participants (planned) · Start Jul 18, 2023 · Primary completion Jul 2027
Drug: Cipaglucosidase alfa; Miglustat · For: Glycogen Storage Disease Type II Infantile Onset
Sites: Gainesville, Florida; Atlanta, Georgia; Durham, North Carolina · 14 sites in all
- A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry DiseasePivotal-lookingRecruiting
Chiesi Farmaceutici S.p.A.Industry
NCT06328608 · 22 participants (planned) · Start Jul 29, 2025 · Primary completion Oct 2028
Drug: PRX-102 1 mg/kg every two weeks · For: Fabry Disease
Sites: Phoenix, Arizona; Atlanta, Georgia; Iowa City, Iowa · 12 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.